rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

DiaMedica Therapeutics Inc.

DMAC · Nasdaq

Health CareBiotechnologyAbove a falling average

DMAC stood above a rising 150-day average in 20 of the last 52 weekly readings, and has been out of that trend for the last 32 weeks. It is 12.6% above that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Above a falling average
Weeks in an uptrend
out for 32
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$7.6M
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
87 (-8)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 20 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$16.2MNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months7
Sale orders, 12 months0
Buyers · sellers1 · 0

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders87-8 on the quarter
New · exited14 · 21
Reported value$87.8M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
COOPERMAN LEON Gadded · filed 14 Aug 20263,450,000$24.3M+1,430,000+70.8%
BlackRock, Inc.added · filed 7 Aug 20262,252,285$15.9M+396,098+21.3%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 2026894,115$6.3M+113,599+14.6%
MILLENNIUM MANAGEMENT LLCreduced · filed 14 Aug 2026845,309$6.0M-90,283−9.6%
STATE STREET CORPadded · filed 7 Aug 2026646,743$4.6M+2,532+0.4%
Bleichroeder LPunchanged · filed 13 Aug 2026382,317$2.7M00.0%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026355,523$2.5M+22,067+6.6%
OSAIC HOLDINGS, INC.added · filed 14 Aug 2026338,107$2.4M+18,432+5.8%
NORTHERN TRUST CORPreduced · filed 13 Aug 2026327,518$2.3M-11,008−3.3%
VANGUARD PORTFOLIO MANAGEMENT LLCadded · filed 13 Aug 2026251,671$1.8M+48,212+23.7%
31 Mar 2023 – 30 Jun 2026
245892Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Dietrich John Pauls Company insiderPresident & CEO · last 10 Aug 20265 · 0
Charles Pauling Semba Company insiderDirector · last 1 Jun 20261 · 0
Daniel J. O'Connor Company insiderDirector · last 1 Jun 20260 · 0
James T. Parsons Company insiderDirector · last 1 Jun 20261 · 0
Julie Krop Company insiderChief Medical Officer · last 1 Jun 20260 · 0
Randall Michael Giuffre Company insiderDirector · last 1 Jun 202611 · 0
Richard Kuntz Company insiderDirector · last 1 Jun 20260 · 0
Scott Kellen Company insiderCFO & Secretary · last 1 Jun 20266 · 0
Tanya Lewis Company insiderDirector · last 1 Jun 20260 · 0
Ab Trill Company insider10% owner · last 25 Nov 20257 · 0
Jan Stahlberg Company insider10% owner · last 27 Aug 202511 · 0
Koch Thomas Von Company insider10% owner · last 23 Jul 20252 · 1

Same industry

MRNA ModernaLeading+147%
ENTX Entera BioLeading+37%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Return on capital employedFY 2025 · to 31 Dec 2025-61.2%
Share count trendFY 2025 · to 27 Mar 20260.3%
Cash and equivalentsFY 2025 · to 31 Dec 2025$15.6M
Free cash flowFY 2025 · to 31 Dec 2025−$29.1M

Analyst forecasts

No analyst forecasts yet.